Skip to main content
Signal8

Can-Fite BioPharma Ltd. (CANF) Form 6-K — Nov 18, 2026

$CANFForm 6-KFiled Nov 18, 2026, 7:03 AM ET0001213900-26-121590Original filing

Can-Fite BioPharma announced that all 247 patients in the interim-analysis cohort of its pivotal Phase III psoriasis study have completed dosing of oral Piclidenoson. The pre-specified interim analysis, conducted by an Independent Data Monitoring Committee under a protocol agreed with both the FDA and EMA, is expected to read out in Q1 2027, evaluating PASI 75 and sPGA 0/1 co-primary endpoints at Week 16.

Key figures

Interim readout
Q1 2027
Piclidenoson dose
3 mg twice daily
Co primary endpoints
["PASI 75 at Week 16","sPGA 0/1 at Week 16"]
Interim cohort patients
247
Safety database subjects
more than 1,500
Patients in clinical studies
over 1,700

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Can-Fite BioPharma Ltd. (CANF) Form 6-K — Nov 18, 2026: AI Analysis | Signal8